Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
Rhea-AI Summary
Trevi Therapeutics (Nasdaq: TRVI) will report its fourth quarter and year‑end 2025 financial results and provide business updates on March 17, 2026 at 4:30 p.m. ET. Senior management will host a conference call and live audio webcast to review results and corporate developments.
Investors can register via the company website at ir.trevitherapeutics.com/news-events/events; registered phone participants receive unique call‑in details by email. An archived replay will be available for 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – TRVI
In the Mar 11 session, TRVI gained 1.53%, reflecting a mild positive market reaction. Argus tracked a trough of -9.3% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Earnings call scheduling | Neutral | +0.0% | Announcement of Q3 2025 results call and corporate update timing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date scheduling news saw a flat price reaction, suggesting limited direct impact from such announcements alone.
Over recent months, Trevi has advanced Haduvio with a Phase 2b JAMA publication showing statistically significant cough-frequency reductions and >60% of treated patients achieving ≥50% reduction, followed by End-of-Phase 2 FDA alignment for two global Phase 3 trials. Management also increased conference visibility. Against this backdrop, the new earnings-date call will provide financials for the year ended December 31, 2025 and business updates following these clinical and regulatory milestones.
Key Terms
idiopathic pulmonary fibrosis medical
interstitial lung disease medical
refractory chronic cough medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call and webcast to be held at 4:30 p.m. ET
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, March 17, 2026, at 4:30 p.m. ET, to provide business updates and review the Company's financial results for the fourth quarter and year ended December 31, 2025.
Conference Call and Webcast
To register for the live conference call and webcast, please visit the ‘Investors & News’ section of the Company’s website or access directly at ir.trevitherapeutics.com/news-events/events. Please note for phone participants: Once registered, you will receive an email with unique call-in details. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.
Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~150,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50
RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Jonathan Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
IR@trevitx.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
